Sign Out
Pregnancy: MPA is contraindicated in women who are pregnant.
Some reports suggest under certain circumstances, an association between intrauterine exposure to progestational drugs in the first trimester of pregnancy and genital abnormalities in fetuses.
Infants from unintentional pregnancies that occur 1 to 2 months after injection of DMPA injectable suspension may be at an increased risk of low birth weight, which, in turn, is associated with an increased risk of neonatal death. The attributable risk is low because pregnancies while on DMPA are uncommon (see Pharmacology: Pharmacokinetics: Distribution under Actions).
If the patient becomes pregnant while using this drug, the patient should be apprised of the potential hazard to the fetus.
Lactation: MPA and its metabolites are excreted in breast milk. There is no evidence to suggest that this presents any hazard to the nursing child, (see Pharmacology: Pharmacokinetics: Distribution under Actions).
Continue with Google